Voyager Therapeutics Announces Positive Preclinical Data From New Vectorized Anti-HER2 Antibody Program At The 26th Society For Neuro-Oncology Annual Meeting

Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors

Cedilla Therapeutics Expands Leadership Team with Key Appointments Across R&D And Finance

Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference

Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors